Leo I Gordon (Leo Gordon)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 30

Top Venues

Blood advances

Blood

Clinical cancer research : an official journal of the American Association for Cancer Research

JCO oncology practice

Northwestern University Feinberg School of Medicine

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Northwestern University Feinberg School of Medicine Jul 01 1979

United States

Faculty :: Hematology/Oncology

University of Chicago Medical Center Jul 01 1978 - Jun 30 1979

United States

Fellowship :: Hematology/Oncology

University of Minnesota Hospital and Clinic Jul 01 1976 - Jun 30 1978

United States

Fellowship :: Hematology

University of Chicago Medical Center Jul 01 1973 - Jun 30 1976

United States

Resident :: Medicine

Publications

Reem Karmali, Rushad Machhi, Narendranath Epperla, Geoffrey Shouse, Jason T Romancik, Tamara K Moyo, Vaishalee P Kenkre, Thomas A Ollila, Lindsey A Fitzgerald, Brian T Hess, Kevin A David, Ishan Roy, Joanna C Zurko, Sayan Mullick Chowdhury, Kaitlin Annunzio, Robert Ferdman, Rahul S Bhansali, Elyse I Harris, Jieqi Liu, Imran A Nizamuddin, Shuo Ma, Jonathan Moreira, Jane N Winter, Barbara Pro, Deborah M Stephens, Alexey V Danilov, Nirav N Shah, Jonathon B Cohen, Stefan K Barta, Pallawi Torka, Leo I Gordon
Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-cell nHL Treated with CAR-T. Blood advances (2024)
Reem Karmali, Rushad Machhi, Narendranath Epperla, Geoffrey Shouse, Jason T Romancik, Tamara K Moyo, Vaishalee Kenkre, Thomas A Ollila, Lindsey Fitzgerald, Brian Hess, Kevin A David, Ishan Roy, Joanna C Zurko, Sayan Mullick Chowdhury, Kaitlin Annunzio, Robert Ferdman, Rahul S Bhansali, Elyse I Harris, Jieqi Liu, Imran Nizamuddin, Shuo Ma, Jonathan Moreira, Jane Winter, Barbara Pro, Deborah M Stephens, Alexey Danilov, Nirav N Shah, Jonathon B Cohen, Stefan K Barta, Pallawi Torka, Leo I Gordon
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy. Blood advances 8 (10) (2024)
Megan Melody, Narendranath Epperla, Geoffrey Shouse, Jason T Romancik, Pamela Blair Allen, Tamara K Moyo, Vaishalee Kenkre, Thomas A Ollila, Lindsey Fitzgerald, Brian Hess, Kevin A David, Megan M Herr, Oluwatobi Odetola, Adam Yuh Lin, Jonathan Moreira, Shuo Ma, Jane N Winter, Ishan Roy, Deborah M Stephens, Alexey Danilov, Nirav N Shah, Stefan K Barta, Matthew Cortese, Jonathon B Cohen, Leo I Gordon, Reem Karmali
Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy. Blood advances 8 (10) (2024)
Reem Karmali, Carlos Galvez, Mehdi Hamadani, Leo I Gordon, Jane N Winter, Shuo Ma, Valerie Nelson, Timothy S Fenske, Nirav N Shah, Deepa Jagadeesh, Andreas K Klein, Irene Helenowski, Ruohui Chen, Xinlei Mi, Adam Petrich, Andrew M Evens, Barbara Pro
A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib for MYC-Aberrant Lymphoid Malignancies: The DACIPHOR Regimen. Blood advances (2024)
Reem Karmali, Carlos Galvez, Mehdi Hamadani, Leo I Gordon, Jane Winter, Shuo Ma, Valerie Nelson, Timothy S Fenske, Nirav N Shah, Deepa Jagadeesh, Andreas Klein, Irene Helenowski, Ruohui Chen, Xinlei Mi, Adam Petrich, Andrew M Evens, Barbara Pro
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen. Blood advances 8 (7) (2024)
Megan Melody, Narendranath Epperla, Geoffrey Shouse, Jason T Romancik, Pamela Blair Allen, Tamara K Moyo, Vaishalee Kenkre, Thomas A Ollila, Lindsey Fitzgerald, Brian Hess, Kevin A David, Megan M Herr, Oluwatobi Odetola, Adam Yuh Lin, Jonathan Moreira, Shuo Ma, Jane N Winter, Ishan Roy, Deborah M Stephens, Alexey Danilov, Nirav N Shah, Stefan K Barta, Matthew Cortese, Jonathon B Cohen, Leo I Gordon, Reem Karmali
Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy. Blood advances 8 (10) (2024)
Reem Karmali, Rushad Machhi, Narendranath Epperla, Geoffrey Shouse, Jason T Romancik, Tamara K Moyo, Vaishalee Kenkre, Thomas A Ollila, Lindsey Fitzgerald, Brian Hess, Kevin A David, Ishan Roy, Joanna C Zurko, Sayan Mullick Chowdhury, Kaitlin Annunzio, Robert Ferdman, Rahul S Bhansali, Elyse I Harris, Jieqi Liu, Imran Nizamuddin, Shuo Ma, Jonathan Moreira, Jane Winter, Barbara Pro, Deborah M Stephens, Alexey Danilov, Nirav N Shah, Jonathon B Cohen, Stefan K Barta, Pallawi Torka, Leo I Gordon
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy. Blood advances 8 (10) (2024)
Reem Karmali, Carlos Galvez, Mehdi Hamadani, Leo I Gordon, Jane Winter, Shuo Ma, Valerie Nelson, Timothy S Fenske, Nirav N Shah, Deepa Jagadeesh, Andreas Klein, Irene Helenowski, Ruohui Chen, Xinlei Mi, Adam Petrich, Andrew M Evens, Barbara Pro
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen. Blood advances 8 (7) (2024)
Megan Melody, Narendranath Epperla, Geoffrey Shouse, Jason T Romancik, Pamela Blair Allen, Tamara K Moyo, Vaishalee Kenkre, Thomas A Ollila, Lindsey Fitzgerald, Brian Hess, Kevin A David, Megan M Herr, Oluwatobi Odetola, Adam Yuh Lin, Jonathan Moreira, Shuo Ma, Jane N Winter, Ishan Roy, Deborah M Stephens, Alexey Danilov, Nirav N Shah, Stefan K Barta, Matthew Cortese, Jonathon B Cohen, Leo I Gordon, Reem Karmali
Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy. Blood advances 8 (10) (2024)
Reem Karmali, Rushad Machhi, Narendranath Epperla, Geoffrey Shouse, Jason T Romancik, Tamara K Moyo, Vaishalee Kenkre, Thomas A Ollila, Lindsey Fitzgerald, Brian Hess, Kevin A David, Ishan Roy, Joanna C Zurko, Sayan Mullick Chowdhury, Kaitlin Annunzio, Robert Ferdman, Rahul S Bhansali, Elyse I Harris, Jieqi Liu, Imran Nizamuddin, Shuo Ma, Jonathan Moreira, Jane Winter, Barbara Pro, Deborah M Stephens, Alexey Danilov, Nirav N Shah, Jonathon B Cohen, Stefan K Barta, Pallawi Torka, Leo I Gordon
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy. Blood advances 8 (10) (2024)
Megan Melody, Narendranath Epperla, Geoffrey Shouse, Jason T Romancik, Pamela Blair Allen, Tamara K Moyo, Vaishalee Kenkre, Thomas A Ollila, Lindsey Fitzgerald, Brian Hess, Kevin A David, Megan M Herr, Oluwatobi Odetola, Adam Yuh Lin, Jonathan Moreira, Shuo Ma, Jane N Winter, Ishan Roy, Deborah M Stephens, Alexey Danilov, Nirav N Shah, Stefan K Barta, Matthew Cortese, Jonathon B Cohen, Leo I Gordon, Reem Karmali
Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy. Blood advances 8 (10) (2024)
Megan Melody, Narendranath Epperla, Geoffrey Shouse, Jason T Romancik, Pamela Blair Allen, Tamara K Moyo, Vaishalee P Kenkre, Thomas A Ollila, Lindsey A Fitzgerald, Brian T Hess, Kevin A David, Megan M Herr, Oluwatobi Odetola, Adam Yuh Lin, Jonathan Moreira, Shuo Ma, Jane N Winter, Ishan Roy, Deborah M Stephens, Alexey V Danilov, Nirav N Shah, Stefan K Barta, Matthew J Cortese, Jonathon B Cohen, Leo I Gordon, Reem Karmali
Subsequent Malignant Neoplasms in Patients Previously Treated with Anti-CD19 CAR T-Cell Therapy. Blood advances (2024)
Michael L Wang, Tanya Siddiqi, Leo I Gordon, Manali Kamdar, Matthew Lunning, Alexandre V Hirayama, Jeremy S Abramson, Jon Arnason, Nilanjan Ghosh, Amitkumar Mehta, Charalambos Andreadis, Scott R Solomon, Ana Kostic, Christine Dehner, Ricardo Espinola, Lily Peng, Ken Ogasawara, Amy Chattin, Laurie Eliason, Maria Lia Palomba
Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma (MCL): Primary Analysis of the MCL Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Reem Karmali, Frédérique St-Pierre, Leo I Gordon
The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma. Future oncology (London, England) (2023)
Jia Ruan, Jasmine M Zain, Brett Palmer, Borko Jovanovic, Xinlei Mi, Alok Swaroop, Jane N Winter, Leo I Gordon, Reem Karmali, Jonathan Moreira, Adam M Petrich, Barbara Pro
Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma. Blood advances (2023)
Jeremy S Abramson, M Lia Palomba, Leo I Gordon, Matthew A Lunning, Michael L Wang, Jon E Arnason, Enkhtsetseg Purev, David G Maloney, Charalambos Babis Andreadis, Alison Sehgal, Scott R Solomon, Nilanjan Ghosh, Christine Dehner, Yeonhee Kim, Ken Ogasawara, Ana Kostic, Tanya Siddiqi
Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood (2023)
Brian T Hill, Shuo Ma, Clive S Zent, Andrea M Baran, Danielle S Wallace, Anjali S Advani, Allison M Winter, Jane N Winter, Leo I Gordon, Reem Karmali, Jane L Liesveld, Deborah A Mulford, Chris Rowland, Andrew Bui, Peter Sportelli, Hari P Miskin, Michael S Weiss, Jonathan W Friedberg, Paul M Barr
Response-Adapted, Time-Limited Venetoclax, Umbralisib and Ublituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood advances (2023)
Reem Karmali, Jeremy S Abramson, Deborah M Stephens, Jeffrey A Barnes, Jane N Winter, Shuo Ma, Juehua Gao, Jason Kaplan, Adam M Petrich, Xinlei Mi, Ephraim P Hochberg, Ronald W Takvorian, Valerie Nelson, Leo I Gordon, Barbara Pro
Ibrutinib Maintenance Following Frontline Treatment in Patients with Mantle Cell Lymphoma. Blood advances (2023)
Nicole Soriano, Kate Berlin, Leo I Gordon
Drug Shortages and Curative Cancer Therapy: The Problem of Dacarbazine and Classical Hodgkin's Lymphoma. JCO oncology practice 18 (7) (2022)
Pamela Blair Allen, Xinyan Lu, Qing Chen, Kaitlyn L O'Shea, Joan S Chmiel, Liron Barnea Slonim, Madina Sukhanova, Hatice Savas, Andrew M Evens, Ranjana Advani, Barbara Pro, Reem Karmali, Brett Palmer, Robert Bayer, Robert M Eisner, Eric Mou, Gary Dillehay, Leo I Gordon, Jane N Winter
Sequential Pembrolizumab and AVD is Highly Effective at any PD-L1 Expression Level in Untreated Hodgkin Lymphoma. Blood advances (2022)
Joanna C Zurko, Imran Nizamuddin, Narendranath Epperla, Kevin A David, Jonathon B Cohen, Tamara Moyo, Thomas A Ollila, Brian T Hess, Ishan Roy, Robert Ferdman, Jieqi Liu, Sayan Mullick Chowdhury, Jason T Romancik, Rahul S Bhansali, Elyse I Harris, Mckenzie Sorrell, Rebecca Masel, Adam S Kittai, Nathan Denlinger, Audrey M Sigmund, Lindsey A Fitzgerald, Carlos Galvez, Shuo Ma, Jane N Winter, Barbara Pro, Leo I Gordon, Alexey V Danilov, Deborah M Stephens, Nirav N Shah, Vaishalee P Kenkre, Stefan K Barta, Pallawi Torka, Geoffrey Shouse, Reem Karmali
Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL. Blood advances (2022)
Adam Yuh Lin, Bongseo Choi, Taehoon Sim, Eva Yang, Hyunjun Choi, Amir Behdad, Dong-Hyun Kim, Leo I Gordon
Enhanced systemic antilymphoma immune response by photothermal therapy with CpG deoxynucleotide-coated nanoparticles. Blood advances 6 (15) (2022)
Adam Yuh Lin, Michael J Cuttica, Michael G Ison, Leo I Gordon
Ibrutinib for chronic lymphocytic leukemia in the setting of respiratory failure from severe COVID-19 infection: Case report and literature review. EJHaem (2020)
Ekaterina A Lesovaya, Alena V Savinkova, Olga V Morozova, Evgeniya S Lylova, Ekaterina M Zhidkova, Evgeny P Kulikov, Kirill I Kirsanov, Anna Klopot, Gleb Baida, Marianna G Yakubovskaya, Leo I Gordon, Ben Readhead, Joel T Dudley, Irina Budunova
A Novel Approach to Safer Glucocorticoid Receptor-Targeted Anti-lymphoma Therapy via REDD1 (Regulated in Development and DNA Damage 1) Inhibition. Molecular cancer therapeutics 19 (9) (2020)
Leo I Gordon, Jason B Kaplan, Rakesh Popat, Howard A Burris, Silvia Ferrari, Sumit Madan, Manish R Patel, Giuseppe Gritti, Dima El-Sharkawi, Ian Chau, John A Radford, Jaime Pérez de Oteyza, Pier Luigi Zinzani, Swaminathan Iyer, William Townsend, Reem Karmali, Harry Miao, Igor Proscurshim, Shining Wang, Yujun Wu, Kate Stumpo, Yaping Shou, Cecilia Carpio, Francesc Bosch
Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (14) (2020)
Reem Karmali, Leo I Gordon
Revving up the immune engine in cHL. Blood 134 (1) (2019)
Radhakrishnan Ramchandren, Ranjana H Advani, Stephen M Ansell, Nancy L Bartlett, Robert Chen, Joseph M Connors, Tatyana Feldman, Andres Forero-Torres, Jonathan W Friedberg, Ajay K Gopal, Leo I Gordon, John Kuruvilla, Kerry J Savage, Anas Younes, Gerald Engley, Thomas J Manley, Keenan Fenton, David J Straus
Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 25 (6) (2019)
Leo I Gordon
Getting to transplant in Hodgkin lymphoma: BVB. Blood 132 (1) (2019)
Matthew J Frank, Patrick M Reagan, Nancy L Bartlett, Leo I Gordon, Jonathan W Friedberg, Debra K Czerwinski, Steven R Long, Richard T Hoppe, Robert Janssen, Albert F Candia, Robert L Coffman, Ronald Levy
In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma. Cancer discovery 8 (10) (2018)
Osman Cen, Karuppiah Kannan, Jessica Huck Sappal, Jie Yu, Mengkun Zhang, Muzaffer Arikan, Ali Ucur, Duran Ustek, Yeter Cen, Leo I Gordon, Richard Longnecker
Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma. mSphere 3 (4) (2018)

Leo I Gordon.css-eqlu8i{font-size:small;padding-left:4px;} (Leo Gordon)

Publication Activity (10 Years)

Top Topics

Top Venues

Leo I Gordon (Leo Gordon)